中文摘要：

目的观察急性冠脉综合征患者分别使用阿托伐他汀与瑞舒伐他汀治疗前后,血清中心型脂肪酸结合蛋白（hearttype fatty acid binding protein,H-FABP）水平的变化。方法选取2014年5月-2015年8月解放军总医院心血管内科收治的122例急性冠脉综合征患者为研究对象,一组患者使用阿托伐他汀治疗（20 mg,1次/d,n=65）,另一组服用瑞舒伐他汀（10mg,1次/d,n=57）,比较两组治疗前后血清中H-FABP水平。结果治疗前阿托伐他汀组H-FABP含量为（9.4±2.3）ng/ml,瑞舒伐他汀组为（8.9±2.7）ng/ml,差异无统计学意义（P〉0.05）。治疗14 d后阿托伐他汀组H-FABP水平为（3.8±3.1）ng/ml,瑞舒伐他汀组为（2.6±2.2）ng/ml,两组均低于治疗前（P〈0.05）;且瑞舒伐他汀组下降更为明显。结论急性冠状动脉综合征患者服用阿托伐他汀或瑞舒伐他汀,均会使血清中H-FABP水平明显下降,且服用瑞舒伐他汀药物组下降更为明显。

英文摘要：

Objective To explore the difference of content of heart-type fatty acid binding protein（H-FABP） in serum of patients with acute coronary syndrome（ACS） treated by atorvastatin or rosuvastatin. Methods One hundred and twenty-two hospitalized patients with acute coronary syndrome were recruited in Chinese PLA General Hospital from May 2014 to August 2015, and they were divided into two treatment groups. One group（n=65） were administrated with atorvastatin（20 mg/d）, and the other group（n=57） were administrated with rosuvastatin（10 mg/d）. The effects of atorvastatin or rosuvastatin on H-FABP in serum of patients with ACS were compared. Results Before treatment, the level of H-FABP in patients who took atorvastatin was（9.4±2.3） ng/ml, and it was（8.9±2.7） ng/ml in patients who took rosuvastatin, showing no significant difference between two groups（P〈0.05）. After 14 days of treatment, the level of H-FABP in patients who took atorvastatin was（3.8±3.1） ng/ml and it was（2.6±2.2） ng/ml in patients who took rosuvastatin, which was significantly lower than those before treatment（P〈0.05）. In addition, the level of H-FABP in patients who took rosuvastatin was significantly lower than that in patients who took atorvastatin [（2.6±2.2） ng/ml vs（3.8±3.1） ng/ml, P〈0.05]. Conclution The H-FABP decreases markedly in patients with acute coronary syndrome after atorvastatin treatment or rosuvastatin treatment. Rosuvastatin is more effective compared with atorvastatin on level of H-FABP in ACS patients.